26
Oct
2022
Variant Bio Strikes New Pharma Bargain, Shares Benefits of Human Genetic Research
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Oct
2022
Bezos Bets on Fred Hutch, Prime Medicine Bucks the Trend, and PacBio Throws Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Oct
2022
Matchpoint Gets $100M to Take Covalent Binders Into Autoimmune Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Oct
2022
Protein Degraders For Outside the Cell: Aetna Wun Trombley on The Long Run
Today’s guest on The Long Run is Aetna Wun Trombley. Aetna is the CEO of South San Francisco-based Lycia Therapeutics. Many in biotech know about targeted protein degraders. Arvinas and Kymera Therapeutics are a couple of the well-known companies that make these drugs which work to inhibit intracellular proteins. This approach has drawn a lot of excitement because it can... Read More
11
Oct
2022
Neumora Snaps Up $112M to Advance Precision Neuroscience Work Through Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2022
Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2022
The Kilimanjaro Climb to Fight Cancer Is Back
I’m taking another biotech team to the highest peak in Africa. Four years after the first team expedition, the Kilimanjaro Climb to Fight Cancer is back with a new crew of 28 biotech executives and investors. Together, we’re going to push ourselves physically, and raise more than $1 million for research at the Fred Hutch Cancer Center. The expedition is... Read More
6
Oct
2022
Red Tree Debuts With $272M, Zeroing In On West Coast Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Sep
2022
Eisai and Biogen Bounce Back, Amylyx Approved, & Illumina’s Big Reveal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Sep
2022
Going Upstream Against Inflammation: Samantha Truex on The Long Run
Today’s guest on The Long Run is Samantha Truex. Samantha is the CEO of Waltham, Mass.-based Upstream Bio. Upstream came out of stealth mode with a $200 million Series A financing in June. It’s a big investment in an antibody aimed at the TSLP receptor. It’s a cytokine – an inflammatory protein – that sits at the top of what... Read More
22
Sep
2022
GSK Lifts Up Spero, AlphaFold Inventors Honored, and a Microbiome Milestone
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Sep
2022
Third Harmonic Revives IPO Market, PDUFA Deadline Nears, & Pfizer Aims mRNA at Flu
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Sep
2022
Pretzel Gets $72.5M for Gene Editing & Small Molecules Against Mitochondrial Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2022
Amylyx’s ALS Surprise, Regeneron’s Eye Franchise Win & Roche Buys Good
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2022
Designing Gene Circuits For Cell Therapies: Tim Lu on The Long Run
Today’s guest on The Long Run is Tim Lu. Tim is the co-founder and CEO of South San Francisco-based Senti Biosciences. Senti is working to develop gene circuits for cell therapies. This is about reprogramming cell therapies with precise genetic instructions on what to do in certain circumstances. The code essentially can tell the cell to kill tumor cells with... Read More
1
Sep
2022
FDA Clears Bivalent Vaccines, Novo Buys Forma, & Novartis R&D Chief Moves On
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Aug
2022
Arch Bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Aug
2022
A Leap for Open Science, Fauci Exits NIH, & Bivalent Boosters on Deck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Aug
2022
Startup Snapshots: Aktis Fetches $84M for Radiopharmaceuticals, 3T Gets $40M for Antigen Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Aug
2022
A Life in Autoimmune Drug Discovery: Jo Viney on The Long Run
Today’s guest on The Long Run is Jo Viney. She is the CEO of Watertown, Mass.-based Seismic Therapeutic. Seismic is working to discover biologic drugs for autoimmune disease. It aims to speed up the process by using machine learning on key aspects – starting with structural biology and including engineering of the protein drugs themselves. Jo has a long track... Read More